Inventiva S.A. (IVA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, good afternoon, everyone, and thank you for joining Inventiva's full year 2025 financial results and business update. Our press release was issued yesterday evening, and this webcast and slides will be available in the investor section on our website following the call. Joining us on the call today are Andrew Obenshain, Chief Executive Officer, Jean Voletier, Chief Financial Officer, and Dr. Jason Campagna, Chief Medical Officer and President of R&D. I would like to remind everyone that statements made during today's conference call and during the Q&A session may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Please refer to slide two of the slides and our SEC and AMF filings for a discussion of associated risks. These statements reflect our views as of today and should not be relied upon as representing our views at any later date. With that, I will now turn it over to Andrew, starting on slide three. Andrew? Thank you, David. Good morning, good afternoon to everyone, and thank you for joining us. Since joining Inventiva six months ago, I've been struck by the depth of scientific conviction behind lanofibrinor and the dedication of this team. Today, every resource, every decision, and every member of this team is now aligned behind a single objective, advancing lanofibrinor towards approval for patients with MASH. Let me start with our main focus, our global phase three clinical trial, Native 3. Enrollment was completed in April 2025 and represented a landmark operational milestone for this company. Today, we are updating the expected timing of our top line readout to Q4, 2026, reflecting the disciplined sequencing of our clinical and biostatistical milestones. We believe that the data fro...